Monitor for CE Mark progress and any upcoming quarterly earnings for revenue and adoption metrics of the LIBERTY System. The patent portfolio expansion is a long-term positive but provides no near-term catalyst.
Price Chart
Executive Summary
Microbot Medical announced the receipt of several new patent approvals across the U.S., Japan, China, and Canada, expanding its global IP portfolio to 44 issued patents and 49 pending applications. The company continues commercializing its LIBERTY Endovascular Robotic System in the U.S. and is pursuing a CE Mark for EU market entry. This is a routine IP portfolio update with no financial data or guidance provided.
Key Facts
- Microbot received new patent approvals in the U.S., Japan, China, and Canada.
- The company now holds 44 issued patents and 49 pending patent applications globally.
- The company continues to expand commercial adoption of the LIBERTY System in the U.S. and is pursuing a CE Mark for international markets.
- The annual meeting is scheduled for December 14, 2026, with a record date of October 15, 2026.
- Deadline for stockholder proposals under Rule 14a-8 is October 27, 2026; deadline for director nominations via Schedule 14N is October 30, 2026.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No revenue or financial data disclosed; commercial adoption pace remains unquantified.
- CE Mark pursuit timeline and outcome are uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047702 |
| Exhibit: ex99-1.htm | 0001493152-26-047702 |
| Document: 0001493152-26-047702-index-headers.html | 0001493152-26-047702 |
| Document: 0001493152-26-047702-index.html | 0001493152-26-047702 |
| Document: 0001493152-26-047702.txt | 0001493152-26-047702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.9570 | awaiting T+1 | — | $1.03 (+7.63%) |
Oct 23, 2026 4d ago | 8-K | $0.9739 $0.9417 | ▼ −3.31% | ▼ −4.02% | $1.03 (+5.76%) |
Oct 20, 2026 7d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $1.03 (+8.71%) |
Oct 6, 2026 21d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $1.03 (−3.74%) |
Oct 6, 2026 21d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $1.03 (−3.74%) |
Sep 28, 2026 29d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $1.03 (−17.60%) |
Aug 11, 2026 11w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $1.03 (−38.69%) |
Jul 21, 2026 14w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $1.03 (−42.78%) |
Jul 7, 2026 16w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $1.03 (−45.79%) |
Jun 30, 2026 17w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $1.03 (−47.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers